tecentriq

Showing 15 posts of 48 posts found.

roche_close

Roche’s Tecentriq improves OS in first-line lung cancer

March 26, 2018
Research and Development, Sales and Marketing Roche, biotech, drugs, lung cancer, pharma, pharmaceutical, tecentriq

Roche has revealed further data from its Phase 3, IMpower150 study, which showed that a combination of Tecentriq and Avastin, …

rocheroof

Roche’s immunotherapy improves PFS but unclear long-term benefit in lung cancer

March 20, 2018
Manufacturing and Production, Research and Development Roche, biotech, drugs, pharma, pharmaceutical, tecentriq

Roche’ Tecentriq needs a big result in the immunotherapy space – it initially burst onto the scene as a third-to-market …

roche_close

Roche Tecentriq combo effective, but is it enough?

December 8, 2017
Medical Communications, Research and Development Roche, biotech, drugs, pharma, pharmaceutical, tecentriq

When Roche announced that its combination treatment of Tecentriq, alongside its own drug Avastin and chemotherapy, successfully extended progression-free survival …

Roche unveils strong combination treatment data in lung cancer

November 20, 2017
Research and Development, Sales and Marketing Cancer, NSCLC< lung cancer, Roche, avastin, immunotherapy, pharma, tecentriq

Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq (atezolizumab) in combination with …

roche

Roche’s Tecentriq scores approvals in metastatic lung and bladder cancer

September 27, 2017
Research and Development, Sales and Marketing Cancer, EMA, EU, European Commission, Roche, bladder cancer, immunotherapy, lung cancer, pharma, tecentriq

It’s good news for Roche as the company’s immunotherapy drug Tecentriq secures approval from the European Commission to be used …

roche__tree

FDA locks down combo immunotherapy trials, Roche added to hold

September 19, 2017
Manufacturing and Production, Sales and Marketing Roche, biotech, drugs, immunotherapy, pharma, pharmaceutical, tecentriq

The FDA has moved to ensure that all immunotherapy trials studying PD-1/L1 agents, alongside immunomodulatory medicines in certain blood cancers …

rocherooflr

Roche blockbuster immunotherapy Tecentriq outclassed by chemo in latest trial

May 10, 2017
Research and Development, Sales and Marketing Roche, tecentriq

It has been revealed that Roche’s immuno-oncology drug Tecentriq (atezolizumab) has failed to hit its primary endpoint in a follow-up …

roche__tree

Roche’s drug scores expanded FDA indication in advanced bladder cancer

April 18, 2017
Manufacturing and Production, Sales and Marketing Genentech, Roche, tecentriq

Roche’s Genentech has revealed that its immunotherapy drug Tecentriq (atezolizumab) is now enjoying an expanded indication in the US after …

shutterstock_141299494

Immunotherapy: The three major treatments that are changing cancer prognoses

March 13, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq

The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …

rick_fair

Genentech oncology head leaves for Bellicum CEO role

February 1, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bellicum, Genentech, Roche, tecentriq

Bellicum Pharmaceuticals has snatched up Genentech’s Rick Fair as its new CEO and President. Fair moves to Bellicum from Genentech …

MHRA accepts Roche’s Tecentriq into Early Access to Medicines scheme

January 25, 2017
Research and Development, Sales and Marketing MHRA, Roche, eams, tecentriq

Roche’s Tecentriq (atezolizumab) has scored another positive opinion, this time from the Medicines and Healthcare products Regulatory Agency (MHRA), which …

roche

Roche’s Tecentriq scores another bladder cancer Priority Review

January 9, 2017
Sales and Marketing Roche, bladder cancer, tecentriq

Roche has announced that its immunotherapy drug Tecenetriq (atezolizumab) has been awarded Priority Review by the FDA for the treatment …

merck_incweb

MSD’s Keytruda early success ends trial early

October 24, 2016
Sales and Marketing MSD, Merck, Roche, keytruda, opdivo, tecentriq

MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …

opdivo_1_1

Failure for BMS’ Opdivo in lung cancer trial

October 10, 2016
Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …

Latest content